AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas

por Elkabets, Moshe, Pazarentzos, Evangelos, Juric, Dejan, Sheng, Qing, Pelossof, Raphael A., Brook, Samuel, Benzaken, Ana Oaknin, Rodon, Jordi, Morse, Natasha, Yan, Jenny Jiacheng, Liu, Manway, Das, Rita, Chen, Yan, Tam, Angela, Wang, Huiqin, Liang, Jinsheng, Gurski, Joseph M., Kerr, Darcy A., Rosell, Rafael, Teixidó, Cristina, Huang, Alan, Ghossein, Ronald A., Rosen, Neal, Bivona, Trever G., Scaltriti, Maurizio, Baselga, José
Publicado en Cancer Cell (2015)